VRDN vs XERS Stock Comparison

XERS currently leads VRDN in this stock comparison, with AIQ scores of 78 vs 58. The clearest difference is value.

Market data as of Nov 15, 2026 market close· AIQ score gap 20 points
VRDN
Healthcare
vs
XERS
Healthcare
VRDN
Viridian Therapeutics, Inc.
Price
$30.87
Day move
+1.28%
AIQ Score
58/100
Best edge
Balanced
Sector
Healthcare
XERS
Xeris Biopharma Holdings, Inc.
Leads
Price
$16.66
Day move
+0.06%
AIQ Score
78/100
Best edge
Value
Sector
Healthcare

What is the main difference between VRDN and XERS?

XERS leads the current stock comparison as Xeris Biopharma Holdings, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Viridian Therapeutics, Inc. vs Xeris Biopharma Holdings, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 9/10

XERS leads

XERS leads by 20 AIQ points, primarily on Value and Quality. Wall Street currently favors VRDN on target upside.

Stable: 5 of 6 evidence groups support XERS, and its current signal state is conflicted.

Evidence agreement: 5 of 6Comparison trend: Stable
VRDN

Viridian Therapeutics, Inc.

AIQ Score
58/100
AIQ Edge Score
6/10
XERS

Xeris Biopharma Holdings, Inc.

Leads
AIQ Score
78/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors XERS over VRDN, 78 versus 58 as of Nov 15, 2026. XERS's advantage is driven primarily by stronger value and quality. XERS also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors VRDN. 5 of 6 covered evidence groups favor XERS today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. XERS lead: Stable — the AIQ differential has held near 20 points over 30 sessions. XERS leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.

Compare Viridian Therapeutics, Inc. and Xeris Biopharma Holdings, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

VRDN
+62.5%
XERS
+580.0%

Price return comparison

Growth of $10,000, price only

VRDN $16,247 · XERS $68,000

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare VRDN and XERS against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

VRDN advantage
0
XERS advantage
  • Value37 vs 68
    XERS +31
  • Quality41 vs 71
    XERS +30
  • Risk Resilience46 vs 55
    XERS +9
  • Momentum91 vs 98
    XERS +7

5 of 6 evidence groups favor XERS. XERS’s edge is concentrated in value and quality.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

VRDN0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 9 active signals are unchanged.

XERS+1 AIQ

Largest factor move: Value +1

No signal started or stopped since the prior session; its 9 active signals are unchanged.

XERS's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — VRDN and XERS both carry a full feed there.

The central trade-off

XERS (Xeris Biopharma Holdings, Inc.): the stronger current systematic profile, led by value and quality.

VRDN (Viridian Therapeutics, Inc.): the counter-case, on analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

XERS

XERS on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

XERS

XERS on combined revenue and EPS growth.

Value

XERS

XERS on the peer-relative Value factor, by 31 points.

Momentum

XERS

XERS on the Momentum factor, by 7 points.

Lower downside

XERS

XERS on Risk Resilience, by 9 points.

Analyst upside

VRDN

VRDN on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors XERS, analyst targets favor VRDN. That disagreement is the most useful thing on this page.

MeasureVRDNXERSNote
Implied upside to target+31.2%-10%VRDN has more room
Target dispersion+12.3%+13.3%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering177Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 6 covered evidence groups favor XERS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreXERS58 vs 78
FundamentalsXERSon balancerevenue growth 89.7% vs 16.4%; EPS growth 22.9% vs 133.3%; TTM ROE -17.4% vs 23.1%; gross margin 93% vs 84.4%; operating margin -17.8% vs 12.7% — XERS takes 3 of 5 decided legs, not all of them
ValuationXERSValue 37 vs 68
TechnicalsXERSPrice vs 50-day 35.7% vs 60.1%; vs 200-day 43.2% vs 112.8%
Risk ResilienceXERSRisk Resilience 46 vs 55
Analyst expectationsVRDNTarget upside 31.2% vs -10%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of VRDN and XERS and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 20 points. (supports the conclusion holding)
  • 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on XERS.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

XERS lead: Stable — the AIQ differential has held near 20 points over 30 sessions.

May 27VRDN leads above the line · XERS leads belowNov 13
Today
XERS +20
58 vs 78
7 sessions ago
XERS +21
56 vs 77
30 sessions ago
XERS +20
56 vs 76
90 sessions ago
XERS +24
47 vs 71

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

VRDNConflicted

5 bullish / 2 bearish / 2 neutral, conflicted

Only VRDN

  • Low Volume Rally Warning — bearish, volume, short horizon (0.42x)
XERSConflicted

6 bullish / 1 bearish / 2 neutral, conflicted

Only XERS

  • 52-Week High Proximity — bullish, risk_regime, long horizon (0.7%)

Both carry 8 more signals that do not separate them: Golden Cross Active, ADX Trend Strengthening, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish, Keltner Channel Breakout, RSI Overbought, TRIX Bullish Signal, Uptrend Structure Active.

XERS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

VRDNNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.28%, AIQ 0 points).

XERSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.06%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1VRDN closes the Value gap — currently 31 points behind, the largest single contributor to XERS's edge.
  2. 2VRDN generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover.
  3. 3XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

XERS leads on balance
MetricVRDNXERS
Revenue growth (YoY)89.7%16.4%
EPS growth (YoY)22.9%133.3%
Gross margin93%84.4%
Operating margin-17.8%12.7%
Return on equity (TTM)-17.4%23.1%
Debt to equity0.424.63

Performance

XERS leads 5 of 6 windows
MetricVRDNXERS
1 week (5 sessions)8.4%9.6%
1 month (20 sessions)62.2%61.6%
3 months (63 sessions)33.7%95.5%
6 months (126 sessions)83.5%167%
Year to date-0.8%112.2%
1 year (252 sessions)6.7%119.5%

Technicals

XERS has the stronger structure
MetricVRDNXERS
RSI (14)77.385.4
ADX (14)5147
Price vs 50-day35.7%60.1%
Price vs 200-day43.2%112.8%
Volatility (1M, annualized)69.7%110.3%

Risk

XERS is the more resilient
MetricVRDNXERS
Beta1.140.07
Sharpe ratio0.431.67
Sortino ratio0.622.99
Max drawdown-60.6%-34.9%
Current drawdown-8.6%0%
Annualized volatility72%57%
Value at risk (95%)-4.2%-4.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, VRDN or XERS?

On the Algovestiq AIQ Score, XERS is the stronger of the two as of Nov 15, 2026, scoring 78 against VRDN's 58. The edge comes from value and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is VRDN or XERS the better buy right now?

XERS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor XERS over VRDN?

The composite weights Quality, Value, Momentum and Risk Resilience. XERS leads Value by 31 points; XERS leads Quality by 30 points; XERS leads Risk Resilience by 9 points. XERS leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by VRDN simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.

Which has more analyst upside, VRDN or XERS?

Analyst price targets imply +31.2% upside for VRDN and -10% for XERS, so the Street currently favors VRDN. That points the opposite way to the AIQ Score, which favors XERS. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, VRDN or XERS?

XERS is the better-valued of the two on the peer-relative Value factor. XERS on the peer-relative Value factor, by 31 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, VRDN or XERS?

XERS on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, VRDN or XERS?

XERS on the Momentum factor, by 7 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, VRDN or XERS?

XERS is the more resilient of the two, so the other name carries the higher downside risk. XERS on Risk Resilience, by 9 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is VRDN more profitable than XERS?

The profitability evidence is mixed: gross margin 93% vs 84.4%; operating margin -17.8% vs 12.7%; ttm roe -17.4% vs 23.1%. VRDN leads on one measure and XERS on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is XERS's lead over VRDN getting stronger or weaker?

XERS lead: Stable — the AIQ differential has held near 20 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the VRDN vs XERS verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: VRDN closes the Value gap — currently 31 points behind, the largest single contributor to XERS's edge; VRDN generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover; XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about VRDN and XERS?

VRDN: 5 bullish / 2 bearish / 2 neutral, conflicted. XERS: 6 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on VRDN is Golden Cross Active (bullish, long horizon). On XERS it is Golden Cross Active (bullish, long horizon).

Compare VRDN and XERS with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.